Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Operating Leases: 2019-2025

Historic Operating Leases for Ultragenyx Pharmaceutical (RARE) over the last 6 years, with Sep 2025 value amounting to $21.7 million.

  • Ultragenyx Pharmaceutical's Operating Leases fell 8.31% to $21.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.7 million, marking a year-over-year decrease of 8.31%. This contributed to the annual value of $30.0 million for FY2024, which is 1.74% down from last year.
  • As of Q3 2025, Ultragenyx Pharmaceutical's Operating Leases stood at $21.7 million, which was down 11.58% from $24.5 million recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's Operating Leases ranged from a high of $36.8 million in Q1 2021 and a low of $14.8 million during Q2 2023.
  • For the 3-year period, Ultragenyx Pharmaceutical's Operating Leases averaged around $25.3 million, with its median value being $25.7 million (2024).
  • Its Operating Leases has fluctuated over the past 5 years, first plummeted by 42.69% in 2023, then spiked by 73.40% in 2024.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Operating Leases (Quarterly) stood at $30.9 million in 2021, then tumbled by 35.89% to $19.8 million in 2022, then spiked by 54.31% to $30.6 million in 2023, then dropped by 1.74% to $30.0 million in 2024, then decreased by 8.31% to $21.7 million in 2025.
  • Its Operating Leases stands at $21.7 million for Q3 2025, versus $24.5 million for Q2 2025 and $27.8 million for Q1 2025.